| scholarly article | Q13442814 |
| review article | Q7318358 |
| P50 | author | Cristoforo Incorvaia | Q61949719 |
| Franco Frati | Q92856617 | ||
| Paola Puccinelli | Q115678688 | ||
| P2093 | author name string | Simonetta Masieri | |
| Silvia Scurati | |||
| Silvia Soffia | |||
| P2860 | cites work | A model for management of sublingual immunotherapy. | Q51679134 |
| Safety of a SQ-standardised grass allergen tablet for sublingual immunotherapy: a randomized, placebo-controlled trial. | Q52935226 | ||
| Low dose sublingual therapy in patients with allergic rhinitis due to house dust mite. | Q54423199 | ||
| Efficacy of sublingual immunotherapy in patients with rhinitis and asthma due to house dust mite. A double-blind study | Q67235010 | ||
| Safety and tolerability of grass pollen tablets in sublingual immunotherapy--a phase-1 study | Q80190684 | ||
| Long-term efficacy of sublingual immunotherapy in patients with perennial rhinitis | Q80422524 | ||
| Anaphylaxis caused by allergen sublingual immunotherapy? | Q81227189 | ||
| A survey of the burden of allergic rhinitis in Europe | Q81419681 | ||
| Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis | Q81439241 | ||
| Do indications to sublingual immunotherapy need to be revised? | Q82680810 | ||
| Importance of patient's education in favouring compliance with sublingual immunotherapy | Q83081674 | ||
| Anaphylactic reaction after the first dose of sublingual immunotherapy with grass pollen tablet | Q83365078 | ||
| Sublingual immunotherapy is not always a safe alternative to subcutaneous immunotherapy | Q84094357 | ||
| Adherence to sublingual immunotherapy: the allergists' viewpoint | Q84477682 | ||
| Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys | Q29615415 | ||
| Safety of sublingual-swallow immunotherapy in children and adults | Q33870761 | ||
| Sub-lingual immunotherapy: World Allergy Organization Position Paper 2009. | Q34090431 | ||
| Allergic rhinitis and its impact on asthma | Q34438438 | ||
| Efficacy of sublingual immunotherapy in the treatment of allergic rhinitis in pediatric patients 3 to 18 years of age: a meta-analysis of randomized, placebo-controlled, double-blind trials | Q34561153 | ||
| Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis | Q34566680 | ||
| Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper | Q34754637 | ||
| The efficacy of sublingual immunotherapy for house dust mites respiratory allergy: results of a GA2LEN meta-analysis | Q35005943 | ||
| Noninjection routes for immunotherapy | Q35087289 | ||
| Sublingual immunotherapy for allergic rhinitis: systematic review and meta-analysis | Q35970094 | ||
| The safety of sublingual-swallow immunotherapy: an analysis of published studies | Q36130311 | ||
| The safety of allergen specific sublingual immunotherapy | Q37239454 | ||
| Effects of sublingual immunotherapy on allergic inflammation | Q37265007 | ||
| Economic studies of immunotherapy: a review | Q37318081 | ||
| Specific immunotherapy for respiratory allergy: state of the art according to current meta-analyses | Q37389177 | ||
| Efficacy of sublingual immunotherapy with grass allergens for seasonal allergic rhinitis: a systematic review and meta-analysis. | Q37776915 | ||
| Efficacy and safety of 5-grass-pollen sublingual immunotherapy tablets in pediatric allergic rhinoconjunctivitis. | Q40403475 | ||
| Coseasonal sublingual immunotherapy reduces the development of asthma in children with allergic rhinoconjunctivitis | Q40523833 | ||
| Patient's compliance with allergen immunotherapy | Q42601969 | ||
| Long-lasting effects of sublingual immunotherapy according to its duration: a 15-year prospective study | Q42678089 | ||
| Sublingual immunotherapy for allergic respiratory diseases: an evaluation of meta-analyses | Q43615448 | ||
| Fatalities from immunotherapy (IT) and skin testing (ST) | Q44852137 | ||
| Post-marketing survey on the safety of sublingual immunotherapy in children below the age of 5 years | Q47795423 | ||
| Efficacy of sublingual allergen vaccination for respiratory allergy in children. Conclusions from one meta-analysis | Q47804869 | ||
| The effect of generalist and specialist care on quality of life in asthma patients with and without allergic rhinitis | Q48887271 | ||
| Long-term clinical efficacy in grass pollen-induced rhinoconjunctivitis after treatment with SQ-standardized grass allergy immunotherapy tablet | Q48897904 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial 3.0 Unported | Q18810331 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | allergic rhinitis | Q272436 |
| immunotherapy | Q1427096 | ||
| P304 | page(s) | 13-17 | |
| P577 | publication date | 2011-02-20 | |
| P1433 | published in | Journal of Asthma and Allergy | Q6294810 |
| P1476 | title | The current role of sublingual immunotherapy in the treatment of allergic rhinitis in adults and children | |
| P478 | volume | 4 |
| Q37390510 | 5-grass pollen tablets achieve disease control in patients with seasonal allergic rhinitis unresponsive to drugs: a real-life study |
| Q35095218 | Omalizumab, an anti-immunoglobulin E antibody: state of the art. |
| Q38002411 | Therapeutic effects and biomarkers in sublingual immunotherapy: a review |
Search more.